Delcath Systems (NASDAQ:DCTH - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Delcath Systems to post earnings of $0.10 per share and revenue of $16.83 million for the quarter.
Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The firm had revenue of $15.10 million during the quarter, compared to analysts' expectations of $14.96 million. During the same quarter last year, the business earned ($0.48) EPS. On average, analysts expect Delcath Systems to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Delcath Systems Price Performance
NASDAQ DCTH traded up $0.32 during mid-day trading on Friday, hitting $12.40. The stock had a trading volume of 340,600 shares, compared to its average volume of 357,703. The firm's 50 day moving average is $12.42 and its 200 day moving average is $12.51. The stock has a market capitalization of $414.57 million, a price-to-earnings ratio of -9.19 and a beta of 0.85. Delcath Systems has a twelve month low of $5.30 and a twelve month high of $16.97.
Analyst Ratings Changes
Several research firms have recently weighed in on DCTH. Craig Hallum raised their price target on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. HC Wainwright boosted their target price on Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $22.75.
Read Our Latest Stock Report on Delcath Systems
About Delcath Systems
(
Get Free Report)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Recommended Stories
Before you consider Delcath Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list.
While Delcath Systems currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
